Mark Suter
Overview
Explore the profile of Mark Suter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1493
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atay C, Medina-Echeverz J, Hochrein H, Suter M, Hinterberger M
Int Rev Cell Mol Biol
. 2023 Aug;
379:87-142.
PMID: 37541728
Cancer immunotherapy relies on unleashing the patient´s immune system against tumor cells. Cancer vaccines aim to stimulate both the innate and adaptive arms of immunity to achieve durable clinical responses....
2.
Endt K, Wollmann Y, Haug J, Bernig C, Feigl M, Heiseke A, et al.
Front Immunol
. 2022 Jul;
13:841471.
PMID: 35774800
Respiratory syncytial virus (RSV) causes a respiratory disease with a potentially fatal outcome especially in infants and elderly individuals. Several vaccines failed in pivotal clinical trials, and to date, no...
3.
Hinterberger M, Giessel R, Fiore G, Graebnitz F, Bathke B, Wennier S, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33579736
Human cancers are extraordinarily heterogeneous in terms of tumor antigen expression, immune infiltration and composition. A common feature, however, is the host's inability to mount potent immune responses that prevent...
4.
Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, et al.
Nat Commun
. 2019 Nov;
10(1):5041.
PMID: 31695037
Virus-based vaccines and appropriate costimulation potently enhance antigen-specific T cell immunity against cancer. Here we report the use of recombinant modified vaccinia virus Ankara (rMVA) encoding costimulatory CD40L against solid...
5.
Robak O, Heimesaat M, Kruglov A, Prepens S, Ninnemann J, Gutbier B, et al.
J Clin Invest
. 2018 May;
128(8):3535-3545.
PMID: 29771684
Broad-spectrum antibiotics are widely used with patients in intensive care units (ICUs), many of whom develop hospital-acquired infections with Pseudomonas aeruginosa. Although preceding antimicrobial therapy is known as a major...
6.
Cheminay C, Korner J, Bernig C, Bruckel M, Feigl M, Schletz M, et al.
Vaccine
. 2018 Mar;
36(18):2427-2434.
PMID: 29599088
Newborns are considered difficult to protect against infections shortly after birth, due to their ineffective immune system that shows quantitative and qualitative differences compared to adults. However, here we show...
7.
Sanos S, Kassub R, Testori M, Geiger M, Patzold J, Giessel R, et al.
Front Immunol
. 2018 Feb;
8:1988.
PMID: 29416534
Bacterial flagellin enhances innate and adaptive immune responses and is considered a promising adjuvant for the development of vaccines against infectious diseases and cancer. Antigen-presenting cells recognize flagellin with the...
8.
Bathke B, Patzold J, Kassub R, Giessel R, Lammermann K, Hinterberger M, et al.
Immunology
. 2017 Dec;
154(2):285-297.
PMID: 29281850
The immunological outcome of infections and vaccinations is largely determined during the initial first days in which antigen-presenting cells instruct T cells to expand and differentiate into effector and memory...
9.
Winkler H, Kornprobst J, Wick P, von Moos L, Trantakis I, Schraner E, et al.
Part Fibre Toxicol
. 2017 Jun;
14(1):21.
PMID: 28645296
Background: Dendritic cells (DCs) are specialized first-line sensors of foreign materials invading the organism. These sentinel cells rely on pattern recognition receptors such as Nod-like or Toll-like receptors (TLRs) to...
10.
Schweneker M, Laimbacher A, Zimmer G, Wagner S, Schraner E, Wolferstatter M, et al.
J Virol
. 2017 Mar;
91(11).
PMID: 28331098
There are currently no approved therapeutics or vaccines to treat or protect against the severe hemorrhagic fever and death caused by Ebola virus (EBOV). Ebola virus-like particles (EBOV VLPs) consisting...